Scarica l'app Stockscreener
139.29
0.04%
-0.2319
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$139.52
Aprire:
$140.66
Volume 24 ore:
230.01K
Relative Volume:
0.08
Capitalizzazione di mercato:
$29.98B
Reddito:
$606.42M
Utile/perdita netta:
$-1.28B
Rapporto P/E:
-21.75
EPS:
-6.403
Flusso di cassa netto:
$-997.58M
1 W Prestazione:
-0.47%
1M Prestazione:
-6.24%
6M Prestazione:
-4.43%
1 anno Prestazione:
+85.79%
Intervallo 1D:
$139.04
$141.78
Intervallo di 1 settimana:
$135.73
$145.64
Portata 52W:
$60.40
$212.75
Insmed Inc Stock (INSM) Company Profile
Nome
Insmed Inc
Settore
Industria
Telefono
908-977-9900
Indirizzo
700 US HIGHWAY 202/206, BRIDGEWATER, NJ
Compare INSM vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
INSM
Insmed Inc
|
139.10 | 30.07B | 606.42M | -1.28B | -997.58M | -6.403 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.71 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
748.83 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
704.89 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
315.09 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
286.21 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Insmed Inc Stock (INSM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-28 | Iniziato | Barclays | Overweight |
| 2026-01-23 | Iniziato | Roth Capital | Buy |
| 2025-12-19 | Ripresa | Truist | Buy |
| 2025-12-04 | Iniziato | Rothschild & Co Redburn | Buy |
| 2025-10-28 | Ripresa | Cantor Fitzgerald | Overweight |
| 2025-10-20 | Iniziato | Wells Fargo | Overweight |
| 2025-08-20 | Iniziato | William Blair | Outperform |
| 2025-08-13 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-05-13 | Iniziato | Jefferies | Buy |
| 2025-02-25 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-04-23 | Iniziato | Truist | Buy |
| 2024-02-15 | Iniziato | Wolfe Research | Outperform |
| 2023-12-08 | Iniziato | Wells Fargo | Overweight |
| 2023-11-20 | Ripresa | JP Morgan | Overweight |
| 2023-07-26 | Iniziato | Guggenheim | Buy |
| 2022-12-09 | Iniziato | Mizuho | Buy |
| 2022-12-07 | Iniziato | Barclays | Overweight |
| 2022-11-18 | Iniziato | BofA Securities | Buy |
| 2022-04-27 | Iniziato | Goldman | Buy |
| 2021-12-06 | Iniziato | JP Morgan | Overweight |
| 2021-10-19 | Ripresa | Monness Crespi & Hardt | Buy |
| 2021-10-19 | Ripresa | Morgan Stanley | Overweight |
| 2021-10-08 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2020-12-17 | Iniziato | Berenberg | Buy |
| 2020-10-12 | Ripresa | Stifel | Buy |
| 2019-09-03 | Iniziato | Goldman | Buy |
| 2019-04-09 | Reiterato | H.C. Wainwright | Buy |
| 2019-02-15 | Aggiornamento | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-01-17 | Aggiornamento | Goldman | Neutral → Buy |
| 2019-01-02 | Iniziato | Canaccord Genuity | Buy |
| 2018-08-06 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2018-07-23 | Iniziato | Goldman | Neutral |
| 2018-04-23 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2018-03-21 | Iniziato | Morgan Stanley | Overweight |
| 2018-01-18 | Iniziato | Credit Suisse | Neutral |
| 2017-09-05 | Reiterato | Evercore ISI | Outperform |
| 2017-08-17 | Iniziato | Evercore ISI | Outperform |
| 2017-07-11 | Iniziato | Robert W. Baird | Outperform |
| 2016-03-15 | Iniziato | Stifel | Buy |
| 2015-11-09 | Downgrade | UBS | Buy → Neutral |
| 2015-10-06 | Reiterato | H.C. Wainwright | Buy |
| 2015-06-09 | Iniziato | Citigroup | Neutral |
| 2014-03-26 | Reiterato | HC Wainwright | Buy |
Mostra tutto
Insmed Inc Borsa (INSM) Ultime notizie
MDA 2026: Insmed launches Phase 1 trial of INS1202 gene therapy for ALS - ALS News Today
FOMO Trade: Is Insmed Incorporated stock a buy or sellEarnings Summary Report & Expert Verified Movement Alerts - baoquankhu1.vn
Insmed at Leerink Global Healthcare Conference: Strategic Insights - Investing.com South Africa
Insmed at Leerink Global Healthcare Conference: Strategic Insights By Investing.com - Investing.com Canada
INSM: ENCORE and BRINSUPRI drive growth as new pipeline assets advance toward major milestones - TradingView
Capital International Investors Raises Stock Position in Insmed, Inc. $INSM - MarketBeat
INSM stock jumps on 2025 preliminary sales, 2026 goals announced - MSN
Fieldview Capital Management LLC Purchases Shares of 20,229 Insmed, Inc. $INSM - MarketBeat
Rhenman & Partners Asset Management AB Has $18.99 Million Stake in Insmed, Inc. $INSM - MarketBeat
Neo Ivy Capital Management Has $1.40 Million Stock Holdings in Insmed, Inc. $INSM - MarketBeat
Neuberger Berman Group LLC Raises Stock Holdings in Insmed, Inc. $INSM - MarketBeat
Insmed, Inc. (NASDAQ:INSM) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat
Victory Capital Management Inc. Boosts Position in Insmed, Inc. $INSM - MarketBeat
Is Insmed Incorporated stock a safe investment in uncertain marketsInsider Selling & Free Technical Pattern Based Buy Signals - Naître et grandir
Insmed Incorporated (INSM) Price Target Raised to $211 at BofA - Finviz
Institution Moves: What are the future prospects of Insmed IncorporatedBear Alert & Accurate Buy Signal Alerts - baoquankhu1.vn
William Lewis Sells 10,699 Shares of Insmed (NASDAQ:INSM) Stock - MarketBeat
Insmed Breaks Below 200-Day Moving AverageNotable for INSM - Nasdaq
Insmed Grants Inducement Awards to 85 New Employees - Intellectia AI
GW&K Investment Management LLC Sells 672,513 Shares of Insmed, Inc. $INSM - MarketBeat
Insmed hands 85 new employees stock units and long-term options - Stock Titan
Picton Mahoney Asset Management Sells 34,001 Shares of Insmed, Inc. $INSM - MarketBeat
Elo Mutual Pension Insurance Co Makes New Investment in Insmed, Inc. $INSM - MarketBeat
INSM Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Pulmonary Arterial Hypertension Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | Merck, Janssen Pharma, Aerovate Therapeutics, Novartis, Insmed Inc, Chugai Pharma, Keros Therap - Barchart.com
Is It Time To Reassess Insmed (INSM) After A 92% One Year Surge? - Yahoo Finance
Insmed, Inc. $INSM Shares Sold by Rafferty Asset Management LLC - MarketBeat
Insmed’s BRINSUPRI Outperformance Puts Commercial Execution And Valuation In Focus - simplywall.st
Insmed Incorporated (INSM): Investor Outlook Reveals A Promising 42% Upside - DirectorsTalk Interviews
Assessing Insmed (INSM) Valuation After Recent Share Price Weakness And Brensocatib Launch Expectations - Yahoo Finance
Insmed at TD Cowen Conference: Strategic Growth and Market Expansion - Investing.com South Africa
INSM: Strong Q4 launch, expanding access, and promising pipeline set stage for significant growth - TradingView
HC Wainwright Has Negative Outlook of Insmed FY2026 Earnings - MarketBeat
William Blair Investment Management LLC Has $223.94 Million Stock Holdings in Insmed, Inc. $INSM - MarketBeat
Insmed Incorporated (INSM) Enters 2026 With Momentum - Finviz
10 Unstoppable Stocks to Buy and Hold for the Next 3 Years - Insider Monkey
Insmed (INSM) director gifts shares and details family holdings - Stock Titan
Insmed, Inc. Experiences Revision in Its Stock Evaluation Amid Financial Performance Trends - Markets Mojo
Artisan Partners Limited Partnership Grows Stock Position in Insmed, Inc. $INSM - MarketBeat
Why Insmed Incorporated (INSM) is One of the Best Strong Buy Healthcare Stocks to Invest In - Finviz
Why Insmed (INSM) Is Down 6.8% After Wider 2025 Losses But Rapid Brinsupri Launch Traction - simplywall.st
Westfield Capital Management Co. LP Lowers Stock Holdings in Insmed, Inc. $INSM - MarketBeat
Thornburg Investment Management Inc. Trims Holdings in Insmed, Inc. $INSM - MarketBeat
Insmed Stock Hits Day Low of $148.24 Amid Price Pressure - Markets Mojo
INSMED Chief Legal Officer Sells Shares Worth Over $3.8 Million - TradingView
Insmed (INSM) CLO exercises options and sells 24,774 shares - Stock Titan
Director David R. Brennan gifts 6,000 INSM (NASDAQ: INSM) shares in Form 4 - Stock Titan
United unveils newly partnered soft mist inhaler; Mannkind sinks - BioWorld MedTech
Insmed (INSM) Q4 2025 Earnings Call Transcript - AOL.com
HC Wainwright Forecasts Insmed's Q3 Earnings (NASDAQ:INSM) - MarketBeat
Brown Advisory Small-Cap Growth Fund's Insmed Inc(INSM) Holding History - GuruFocus
Insmed Inc Azioni (INSM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Insmed Inc Azioni (INSM) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Lewis William | Chair and CEO |
Mar 05 '26 |
Option Exercise |
24.94 |
10,699 |
266,840 |
311,884 |
| Lewis William | Chair and CEO |
Mar 05 '26 |
Sale |
146.03 |
10,699 |
1,562,328 |
301,185 |
| Smith Michael Alexander | Chief Legal Officer |
Feb 24 '26 |
Option Exercise |
17.07 |
20,248 |
345,633 |
76,645 |
| Smith Michael Alexander | Chief Legal Officer |
Feb 24 '26 |
Sale |
155.77 |
24,774 |
3,859,157 |
51,871 |
0.99%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):